Neuroone Medical Technologies is trading 6% down at $2.50 as investors react to a combination of insider selling and the expansion of the company’s at-the-market equity program.
- Director Mark Christianson’s sale of 10,000 shares on June 30 has fueled concerns regarding insider sentiment and recent selling patterns.
- The expansion of the company’s at-the-market equity program has added to the downside pressure, raising investor fears of potential share dilution.
- These developments have extended the negative momentum seen in the stock over the past week.